ITGAX and bronchiolitis obliterans syndrome: Concerning APCs, analyses of peri- and intra-tumoral CD11c+ demonstrated that these cells are among the most significant immune biomarkers that differentiate GO from BO patients (p=0.0002 and p=0.001, respectively) (Table 1 and Figure 2).